• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.杜氏利什曼原虫野外分离株对米替福新和两性霉素B的体外敏感性：与葡萄糖酸锑钠敏感性的相关性及对流行地区治疗的意义
Antimicrob Agents Chemother. 2009 Feb;53(2):835-8. doi: 10.1128/AAC.01233-08. Epub 2008 Nov 17.
2
Antimony susceptible : evidence from drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.锑敏感：来自前米替福新时代和后米替福新时代间，从卡拉巴肿后皮肤利什曼病患者分离的寄生虫药物敏感性获得的证据。
Microbiol Spectr. 2024 Jun 4;12(6):e0402623. doi: 10.1128/spectrum.04026-23. Epub 2024 May 7.
3
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.十六烷基磷酸胆碱（米替福新）、两性霉素B脂质体和葡萄糖酸锑钠（喷他脒）对免疫缺陷型重度联合免疫缺陷（scid）小鼠体内杜氏利什曼原虫的活性。
Antimicrob Agents Chemother. 2001 Jun;45(6):1872-5. doi: 10.1128/AAC.45.6.1872-1875.2001.
4
[A case of antimony resistant kala-azar cured with amphotericin B].[1例用两性霉素B治愈的抗锑性黑热病]
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2007 Jun;25(3):inside front page.
5
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.印度黑热病野外分离株对葡萄糖酸锑钠治疗的耐药性在体外和体内实验模型中持续存在。
Parasitol Res. 2005 Jun;96(4):216-23. doi: 10.1007/s00436-005-1339-1. Epub 2005 May 3.
6
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.来自印度的实验室确诊的对米替福新耐药的内脏利什曼病病例。
Parasit Vectors. 2017 Jan 31;10(1):49. doi: 10.1186/s13071-017-1969-z.
7
Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.杜氏利什曼原虫：锑耐药两性霉素B敏感分离株的体外研究
Exp Parasitol. 2006 Dec;114(4):247-52. doi: 10.1016/j.exppara.2006.03.016. Epub 2006 May 23.
8
Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.比哈尔邦治疗内脏利什曼病时对葡萄糖酸锑钠无反应的程度。
Natl Med J India. 2005 May-Jun;18(3):131-3.
9
Leishmania resistance to miltefosine associated with genetic marker.利什曼原虫对米替福新的耐药性与遗传标记有关。
Emerg Infect Dis. 2012 Apr;18(4):704-6. doi: 10.3201/eid1804.110841.
10
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.米替福新治疗内脏利什曼病和黑热病后皮肤利什曼病病例中利什曼原虫分离株的药物敏感性。
PLoS Negl Trop Dis. 2012;6(5):e1657. doi: 10.1371/journal.pntd.0001657. Epub 2012 May 22.

引用本文的文献

1
Efficacy of meglumine antimoniate treatment on boxer skin lesions: case report.葡甲胺锑酸盐治疗拳击手皮肤病变的疗效：病例报告。
Front Vet Sci. 2025 Jun 30;12:1600004. doi: 10.3389/fvets.2025.1600004. eCollection 2025.
2
Genomic characterization of Leishmania (V.) braziliensis associated with antimony therapeutic failure and variable in vitro tolerance to amphotericin B.与锑治疗失败及对两性霉素B的体外耐受性可变相关的巴西利什曼原虫（Viannia亚属）的基因组特征
Sci Rep. 2025 Apr 15;15(1):12973. doi: 10.1038/s41598-025-96849-z.
3
Antimony susceptible : evidence from drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.锑敏感：来自前米替福新时代和后米替福新时代间，从卡拉巴肿后皮肤利什曼病患者分离的寄生虫药物敏感性获得的证据。
Microbiol Spectr. 2024 Jun 4;12(6):e0402623. doi: 10.1128/spectrum.04026-23. Epub 2024 May 7.
4
Antimony resistance mechanism in genetically different clinical isolates of Indian Kala-azar patients.印度黑热病患者不同临床分离株的锑耐药机制。
Front Cell Infect Microbiol. 2022 Nov 2;12:1021464. doi: 10.3389/fcimb.2022.1021464. eCollection 2022.
5
Isolation, typing, and drug susceptibility of Leishmania (Leishmania) infantum isolates from dogs of the municipality of Embu das Artes, an endemic region for canine leishmaniasis in Brazil.从巴西犬利什曼病流行地区恩布杜达斯阿特斯市的犬中分离、鉴定和药敏试验利什曼原虫（利什曼原虫）分离株。
Parasitol Res. 2022 Sep;121(9):2683-2695. doi: 10.1007/s00436-022-07594-5. Epub 2022 Jul 8.
6
In-Depth Quantitative Proteomics Characterization of In Vitro Selected Miltefosine Resistance in .体外筛选的米替福新耐药性的深度定量蛋白质组学表征 。（原文表述似乎不完整，缺少具体研究对象等关键信息）
Proteomes. 2022 Mar 31;10(2):10. doi: 10.3390/proteomes10020010.
7
Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.在使用米替福新和别嘌醇治疗的狗中，利什曼原虫对米替福新和两性霉素 B 的耐药性增加。
Parasit Vectors. 2021 Dec 9;14(1):599. doi: 10.1186/s13071-021-05100-x.
8
Proteomic Analysis of Membrane Components Reveals the Role of Activated Protein C Kinase in Host-Parasite Interaction.膜成分的蛋白质组学分析揭示了活化蛋白C激酶在宿主-寄生虫相互作用中的作用。
Pathogens. 2021 Sep 15;10(9):1194. doi: 10.3390/pathogens10091194.
9
In Vitro Susceptibility to Miltefosine of (syn.  ) Isolates from Different Geographical Areas in Brazil.巴西不同地理区域分离的（同义词： ）对米替福新的体外敏感性
Microorganisms. 2021 Jun 5;9(6):1228. doi: 10.3390/microorganisms9061228.
10
Metabolite Biomarkers of Antimony Resistance.抗锑代谢产物生物标志物。
Cells. 2021 Apr 30;10(5):1063. doi: 10.3390/cells10051063.

本文引用的文献

1
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.米替福新治疗利什曼病：知情临床风险管理的临床证据。
Ther Clin Risk Manag. 2007 Oct;3(5):733-40.
2
Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.膜修饰作为杜氏利什曼原虫抗锑机制的可能性。
Parasitol Int. 2007 Mar;56(1):77-80. doi: 10.1016/j.parint.2006.10.005. Epub 2006 Dec 12.
3
A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death.一项蛋白质组学筛选表明，热休克蛋白83（HSP83）和一种小型动基体钙蛋白酶相关蛋白通过调节药物诱导的程序性细胞死亡，参与杜氏利什曼原虫临床现场分离株的耐药性。
Mol Cell Proteomics. 2007 Jan;6(1):88-101. doi: 10.1074/mcp.M600319-MCP200. Epub 2006 Oct 17.
4
Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.内脏利什曼病，即黑热病（KA）：通过黑热病后皮肤利什曼病的人传人传播导致对锑难治性的高发生率。
J Infect Dis. 2006 Aug 1;194(3):302-6. doi: 10.1086/505079. Epub 2006 Jun 22.
5
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.利什曼原虫对米替福新产生实验性耐药的机制：对临床应用的启示
Drug Resist Updat. 2006 Feb-Apr;9(1-2):26-39. doi: 10.1016/j.drup.2006.04.001.
6
Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.磷脂转运和米替福新效力在利什曼原虫中既需要杜氏利什曼原虫米替福新转运蛋白，也需要新蛋白LdRos3。
J Biol Chem. 2006 Aug 18;281(33):23766-75. doi: 10.1074/jbc.M605214200. Epub 2006 Jun 19.
7
Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.一些苏丹黑热病患者对两性霉素B脂质体无反应。
Trans R Soc Trop Med Hyg. 2007 Jan;101(1):19-24. doi: 10.1016/j.trstmh.2006.02.005. Epub 2006 May 26.
8
Drug resistance in leishmaniasis.利什曼病中的耐药性。
Clin Microbiol Rev. 2006 Jan;19(1):111-26. doi: 10.1128/CMR.19.1.111-126.2006.
9
The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.来自秘鲁和尼泊尔的利什曼原虫临床分离株对米替福新的敏感性。
Am J Trop Med Hyg. 2005 Aug;73(2):272-5.
10
Availability of miltefosine for the treatment of kala-azar in India.在印度可获得用于治疗黑热病的米替福新。
Bull World Health Organ. 2005 May;83(5):394-5. Epub 2005 Jun 24.

杜氏利什曼原虫野外分离株对米替福新和两性霉素B的体外敏感性：与葡萄糖酸锑钠敏感性的相关性及对流行地区治疗的意义

In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

作者信息

Kumar Dhiraj, Kulshrestha Arpita, Singh Ruchi, Salotra Poonam

机构信息

Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India.

出版信息

Antimicrob Agents Chemother. 2009 Feb;53(2):835-8. doi: 10.1128/AAC.01233-08. Epub 2008 Nov 17.

DOI:10.1128/AAC.01233-08
PMID:19015344
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2630609/
Abstract

Indian Leishmania donovani isolates (n = 19) from regional zones representing various levels of antimony resistance displayed significantly (P < 0.01) correlated results with respect to in vitro susceptibility to the antileishmanial drugs sodium antimony gluconate, amphotericin B, and Miltefosine, raising the possibility of cross-resistance mechanisms operating in the field isolates. The results of gene expression analysis of LdMT and LdRos3 were suggestive of alternate mechanisms of Miltefosine susceptibility in the isolates.

摘要

来自代表不同锑抗性水平的区域的19株印度杜氏利什曼原虫分离株，在体外对抗利什曼原虫药物葡萄糖酸锑钠、两性霉素B和米替福新的敏感性方面显示出显著（P < 0.01）相关的结果，这增加了野外分离株中存在交叉抗性机制的可能性。LdMT和LdRos3的基因表达分析结果提示了分离株中米替福新敏感性的替代机制。